Financial terms of the transaction were not disclosed.
“Members of Idera’s senior management will invest alongside TA Associates and will maintain a significant equity interest in the company,” TA said in a press release.
(Idera is not to be confused with Idera Pharmaceuticals, a clinical stage biotechnology company headquartered in Cambridge.)
Hythem T. El-Nazer and Ashutosh Agrawal, both directors at TA Associates, will join Idera’s board of directors.
“Idera is a very attractive investment for TA Associates as an emerging leader in the infrastructure software market, led by an experienced management team with a strong track record of driving organic and inorganic growth,” El-Nazer said in a statement. “The company has shown a commitment to increasing its product line of robust application performance monitoring software, expanding its addressable market and identifying opportunities for continued growth. We look forward to working with Idera’s talented management team to create value through organic growth and acquisitions.”Chris Reidy can be reached at email@example.com.